請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53957
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊曜宇 | |
dc.contributor.author | Yao-Yin Chang | en |
dc.contributor.author | 張耀尹 | zh_TW |
dc.date.accessioned | 2021-06-16T02:34:38Z | - |
dc.date.available | 2015-07-31 | |
dc.date.copyright | 2015-07-31 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-28 | |
dc.identifier.citation | 1. Olopade OI, Grushko TA, Nanda R, Huo D: Advances in breast cancer: pathways to personalized medicine. Clinical Cancer Research 2008, 14:7988-7999.
2. Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L: African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 2010, 116:4926-4932. 3. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. The New England Journal of Medicine 2009, 360:790-800. 4. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. The Lancet Oncology 2007, 8:235-244. 5. Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. The New England Journal of Medicine 2010, 363:1938-1948. 6. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32. 7. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007, 110:876-884. 8. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Journal of Clinical Oncology 2006, 24:5652-5657. 9. Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, et al: Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003, 98:1569-1577. 10. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 2007, 13:4429-4434. 11. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, Rosenberg CL: Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Research 2009, 11:R18. 12. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute 2003, 95:1482-1485. 13. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW: Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast cancer research and treatment 2009, 113:357-370. 14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 15. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728. 16. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U: Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. Breast cancer research and treatment 2008, 107:405-414. 17. Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, Kim S, Choe JH, Lee JE, Kim JH, et al: The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast cancer research and treatment 2011, 126:471-478. 18. Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Shin KH, et al: Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast cancer research and treatment 2010, 120:627-637. 19. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006, 49:10-21. 20. Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, et al: Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2008, 116:923-930. 21. Constantinidou A, Jones RL, Reis-Filho JS: Beyond triple-negative breast cancer: the need to define new subtypes. Expert review of anticancer therapy 2010, 10:1197-1213. 22. Criscitiello C, Azim HA, Jr., Schouten PC, Linn SC, Sotiriou C: Understanding the biology of triple-negative breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012, 23 Suppl 6:vi13-18. 23. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research 2004, 10:5367-5374. 24. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, et al: Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718. 25. Marchio C, Weigelt B, Reis-Filho JS: Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). Journal of clinical pathology 2010, 63:220-228. 26. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R: Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010, 23:205-212. 27. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, et al: Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010, 21:1974-1981. 28. Ries LAG, Melbert D, Krapcho M et al (2006) SEER cancer statistics review, 1975-2004, National Cancer Institute, Bethesda, MD. 29. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M: Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2009, 153:13-17. 30. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, et al: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS medicine 2010, 7:e1000279. 31. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. European journal of cancer 2009, 45:2792-2798. 32. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 2008, 26:1275-1281. 33. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2006, 19:264-271. 34. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65. 35. Hamperl H: The myothelia (myoepithelial cells). Normal state; regressive changes; hyperplasia; tumors. Current topics in pathology Ergebnisse der Pathologie 1970, 53:161-220. 36. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 37. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10869-10874. 38. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast cancer research and treatment 2008, 111:27-44. 39. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research 2008, 14:1368-1376. 40. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, et al: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clinical Cancer Research 2009, 15:2302-2310. 41. Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS: Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Research 2007, 9:404; author reply 405. 42. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiology, Biomarkers & Prevention 2007, 16:439-443. 43. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, et al: Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010, 29:2013-2023. 44. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation 2011, 121:2750-2767. 45. Yarden Y, Schlessinger J: Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987, 26:1443-1451. 46. Oda K, Matsuoka Y, Funahashi A, Kitano H: A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular systems biology 2005, 1:2005 0010. 47. Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY: High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014, 27:1212-1222. 48. Sood N, Nigam JS: Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer. Pathology research international 2014, 2014:141864. 49. Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J, Oyama T: Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast cancer 2014, 21:66-74. 50. Herbst RS: Review of epidermal growth factor receptor biology. International journal of radiation oncology, biology, physics 2004, 59:21-26. 51. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI: ErbB receptors: from oncogenes to targeted cancer therapies. The Journal of clinical investigation 2007, 117:2051-2058. 52. Sabattini S, Mancini FR, Marconato L, Bacci B, Rossi F, Vignoli M, Bettini G: EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival. Veterinary and comparative oncology 2014, 12:237-248. 53. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. European journal of cancer 2001, 37 Suppl 4:S9-15. 54. Zlobec I, Vuong T, Hayashi S, Haegert D, Tornillo L, Terracciano L, Lugli A, Jass J: A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. British journal of cancer 2007, 96:793-800. 55. Taylor TE, Furnari FB, Cavenee WK: Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Current cancer drug targets 2012, 12:197-209. 56. Lopez-Gines C, Gil-Benso R, Ferrer-Luna R, Benito R, Serna E, Gonzalez-Darder J, Quilis V, Monleon D, Celda B, Cerda-Nicolas M: New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010, 23:856-865. 57. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine 2004, 350:2129-2139. 58. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 59. Geurs F, Vandewaeter S, Ponette S, Ponette J, Knape S, Demetter P: Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer. Journal of gastrointestinal cancer 2008, 39:26-28. 60. Grigorean VT, Ciuhu AN, Rahnea Nita G, Strambu V, Straja DN, Popescu M, Sandu AM, Rahnea Nita RA: Efficacy of cetuximab in metastatic colon cancer - case report. Chirurgia 2014, 109:383-389. 61. Nechushtan H, Vainer G, Stainberg H, Salmon AY, Hamburger T, Peretz T: A phase 1/2 of a combination of cetuximab and taxane for 'triple negative' breast cancer patients. Breast 2014, 23:435-438. 62. Tredan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, et al: Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. Clinical breast cancer 2015, 15:8-15. 63. Baselga J, Gomez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pego A, Chan A, et al: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology 2013, 31:2586-2592. 64. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, et al: TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology 2012, 30:2615-2623. 65. Oakman C, Viale G, Di Leo A: Management of triple negative breast cancer. Breast 2010, 19:312-321. 66. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 67. Duncan JA, Reeves JR, Cooke TG: BRCA1 and BRCA2 proteins: roles in health and disease. Molecular pathology : MP 1998, 51:237-247. 68. Yoshida K, Miki Y: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer science 2004, 95:866-871. 69. Friedenson B: The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC cancer 2007, 7:152. 70. Venkitaraman AR: Tracing the network connecting BRCA and Fanconi anaemia proteins. Nature reviews Cancer 2004, 4:266-276. 71. Wooster R, Weber BL: Breast and ovarian cancer. The New England Journal of Medicine 2003, 348:2339-2347. 72. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8418-8423. 73. Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD: Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clinical Cancer Research 2005, 11:4003-4011. 74. Laakso M, Loman N, Borg A, Isola J: Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005, 18:1321-1328. 75. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical Cancer Research 2005, 11:5175-5180. 76. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Jr., Ellis P, et al: Dissecting the heterogeneity of triple-negative breast cancer. Journal of Clinical Oncology 2012, 30:1879-1887. 77. Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T: PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. The EMBO journal 2009, 28:2601-2615. 78. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. 79. Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013, 15:R88. 80. Manie E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, et al: High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer research 2009, 69:663-671. 81. Kang SP, Martel M, Harris LN: Triple negative breast cancer: current understanding of biology and treatment options. Current opinion in obstetrics & gynecology 2008, 20:40-46. 82. Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Shin JH, Ko EY, Han BK, et al: Clinical relevance of TNM staging system according to breast cancer subtypes. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011, 22:1554-1560. 83. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast cancer research and treatment 2009, 115:423-428. 84. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 85. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome biology 2007, 8:R157. 86. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 87. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679. 88. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC: A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 2010, 12:R85. 89. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, Saab KR, Osherov V, Widlund HR, Gasser M, et al: VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer research 2011, 71:1474-1485. 90. Smola MG, Estelberger W, Reiter M, Schauenstein K, Schauenstein E: Sigma S, a measure of reactive sulfur groups of immunoglobulin G, is a sensitive tumor marker discriminating different stages of breast cancer. Cancer 1991, 68:1026-1030. 91. Wolfer A, Ramaswamy S: MYC and metastasis. Cancer research 2011, 71:2034-2037. 92. Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro I, Potapenko T: MYC is a metastasis gene for non-small-cell lung cancer. PLoS One 2009, 4:e6029. 93. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584. 94. Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nature reviews Genetics 2010, 11:597-610. 95. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Research 2004, 14:1902-1910. 96. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature cell biology 2009, 11:228-234. 97. Neilson JR, Zheng GX, Burge CB, Sharp PA: Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes & development 2007, 21:578-589. 98. Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, Sheng W, He X, Du X: MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer research 2011, 71:2582-2589. 99. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S, Lee B: MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood 2009, 114:404-414. 100. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:13944-13949. 101. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:2257-2261. 102. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer research 2005, 65:7065-7070. 103. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer research 2005, 65:9628-9632. 104. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803. 105. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:3207-3212. 106. Calin GA, Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer research 2006, 66:7390-7394. 107. Schulte JH, Marschall T, Martin M, Rosenstiel P, Mestdagh P, Schlierf S, Thor T, Vandesompele J, Eggert A, Schreiber S, et al: Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic acids research 2010, 38:5919-5928. 108. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nature protocols 2008, 3:1101-1108. 109. Betel D, Wilson M, Gabow A, Marks DS, Sander C: The microRNA.org resource: targets and expression. Nucleic acids research 2008, 36:D149-153. 110. Betel D, Koppal A, Agius P, Sander C, Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome biology 2010, 11:R90. 111. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, Wahl AF: Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. The Journal of biological chemistry 1997, 272:12650-12661. 112. Bates S, Rowan S, Vousden KH: Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene 1996, 13:1103-1109. 113. Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF: Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. The Journal of biological chemistry 1996, 271:6050-6061. 114. Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, DePaoli-Roach AA, Horne MC: Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. The Journal of biological chemistry 2002, 277:27449-27467. 115. Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A: Decreased expression of cyclin G2 is significantly linked to the malignant transformation of papillary carcinoma of the thyroid. Anticancer research 2003, 23:2335-2338. 116. Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT: Cyclin G2 dysregulation in human oral cancer. Cancer research 2004, 64:8980-8986. 117. Weiner MP, Costa GL, Schoettlin W, Cline J, Mathur E, Bauer JC: Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction. Gene 1994, 151:119-123. 118. Zavadil J, Bottinger EP: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774. 119. Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R: beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 2004, 23:2672-2680. 120. Bates RC, Mercurio AM: Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Molecular Biology of the Cell 2003, 14:1790-1800. 121. Fischer AN, Herrera B, Mikula M, Proell V, Fuchs E, Gotzmann J, Schulte-Hermann R, Beug H, Mikulits W: Integration of Ras subeffector signaling in TGF-beta mediated late stage hepatocarcinogenesis. Carcinogenesis 2005, 26:931-942. 122. Liu Y, Teige I, Birnir B, Issazadeh-Navikas S: Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nature Medicine 2006, 12:518-525. 123. Alevizos I, Mahadevappa M, Zhang X, Ohyama H, Kohno Y, Posner M, Gallagher GT, Varvares M, Cohen D, Kim D, et al: Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene 2001, 20:6196-6204. 124. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574. 125. Houldsworth J, Heath SC, Bosl GJ, Studer L, Chaganti RS: Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 2002, 13:257-264. 126. Ahmed S, Al-Saigh S, Matthews J: FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. Molecular cancer research : MCR 2012, 10:636-648. 127. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS: Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. The Journal of biological chemistry 2006, 281:16272-16278. 128. Fu G, Peng C: Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells. Oncogene 2011, 30:3953-3966. 129. Ellison-Zelski SJ, Solodin NM, Alarid ET: Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Molecular and cellular biology 2009, 29:4949-4958. 130. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, et al: SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 2012, 487:380-384. 131. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell 2006, 9:189-198. 132. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72:397-402. 133. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. The Journal of biological chemistry 2007, 282:32582-32590. 134. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sorensen KD, Ulhoi B, Borre M, Kjems J, Dyrskjot L, Orntoft TF: miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010, 29:1073-1084. 135. Sachdeva M, Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer research 2010, 70:378-387. 136. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clinical Cancer Research 2011, 17:1722-1730. 137. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM: MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009, 50:113-121. 138. Ernst A, Campos B, Meier J, Devens F, Liesenberg F, Wolter M, Reifenberger G, Herold-Mende C, Lichter P, Radlwimmer B: De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene 2010, 29:3411-3422. 139. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L: miR-19 is a key oncogenic component of mir-17-92. Genes & development 2009, 23:2839-2849. 140. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S, Lam EW: Definition of microRNA | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53957 | - |
dc.description.abstract | 中文摘要
導論 三陰性乳癌是指乳癌細胞內部的雌激素受體、黃體激素受體和細胞膜上的人類表皮因子受體皆為陰性的乳癌。與其他類型的乳癌相比,三陰性乳癌本質上較具有侵略性,而且其腫瘤細胞增長的機制也與其他類型的乳癌不同。目前醫療上尚未有一個標靶藥物可對三陰性乳癌進行有效的治療,因此三陰性乳癌的治療模式相對貧乏,且其病患術後遠處轉移復發的比例也較高。近年來有許多的研究資料顯示異常的信使核糖核酸(messenger RNA)和微型核糖核酸(microRNA)基因表現對人類腫瘤細胞的增生和惡化有著重大的影響,然而目前醫學研究上對於三陰性乳癌的基因表現及其內部調控機制仍然不甚明瞭。國外有專家學者提出使用數個關鍵基因的基因表現做為乳癌病患預後的一個指標,但其研究結果通常只適用在雌激素受體和黃體激素受體陽性的乳癌病患族群,無法準確的預估三陰性乳癌病患術後腫瘤轉移的可能性。因此本研究著重於探討利用三陰性乳癌的信使核糖核酸的基因表現,做為三陰性乳癌病患其術後癌細胞遠處轉移預測的一個方式,以及近年來腫瘤醫學的熱門研究重心微型核糖核酸在三陰性乳癌細胞內的表現特徵。 研究方法 本研究中所使用的五十一個三陰性乳癌檢體和一百零六個管腔型乳癌檢體及臨床病理資料皆由台大醫院臨床醫師提供。研究團隊使用寡核苷酸微陣列晶片技術來量測乳癌檢體內的信使核糖核酸基因表現,再將各個檢體內的基因表現量做正規化,接著合併分析三陰性乳癌病患的腫瘤遠處轉移臨床資料和其腫瘤內的信使核糖核酸基因表現以取得其統計上的關聯性。此外研究團隊也使用高通量定序技術對二十四個三陰性乳癌檢體和十四個其周遭正常乳房組織檢體中的微型核糖核酸表現進行量測,之後用百分位正規化的方式為每一個檢體中的微型核糖核酸表現做前置處理,再使用統計檢定分析來找出在三陰性乳癌中有顯著差異表現的微型核糖核酸。研究團隊進一步針對這些微型核糖核酸進行定量即時聚合酶鏈鎖反應的實驗,確認所找到的微型核糖核酸在三陰性乳癌和正常乳房組織中的確有顯著的差異表現。作者應用微型核糖核酸調控基因預測的miRanda演算法,找出可能被這些微型核糖核酸所調控的基因,並用螢光素酶檢測法做進一步的驗證。本論文並深入的探討前人文獻中所提出關於這些顯著表現的微型核糖核酸在其他人類癌症腫瘤內所調控的基因與病理機制。 研究結果與討論 作者使用階層式集群法來分析三陰性乳癌和管腔型乳癌的基因表現,發現大部分(94%)的三陰性乳癌皆帶有顯著高量表現的類基底型角質素基因,管腔型乳癌則無此基因表現特徵。作者接著在遠處腫瘤轉移的三陰性乳癌病患族群中找出顯著表現的信使核糖核酸基因,並使用留一交互檢驗法和接受器操作特性曲線來找出一個由四十五個基因所組成之優化預測模組,其預測準確度在本研究病患族群可達到98%。此外這個四十五個基因的預測模組在另一個獨立的三陰性乳癌病患族群也可以有效的預測其病患術後腫瘤復發的狀況,然而若使用其他已發表的乳癌預後預測基因模組則無法在此病患族群做準確的預測。作者進一步的研究這四十五個基因,發現到有許多的基因都與調控人體免疫反應和發炎機制的轉化生長因子β訊號傳遞密切的相關。在微型核糖核酸的研究方面,團隊使用高通量定序技術找到一組由二十五個顯著差異表現的微型核糖核酸所組成的辨識模組,可藉由此模組的微型核糖核酸表現量精確地分辨三陰性乳癌組織和周遭正常乳房組織。作者並發現許多在三陰性乳癌中顯著表現的微型核糖核酸皆群聚於人類染色體中的七個不同的基因位點,且進一步用定量即時聚合酶鏈鎖反應實驗來驗證這些微型核糖核酸群聚組的表現量。作者並藉由螢光素酶檢測法發現在三陰性乳癌內顯著表現的微型核糖核酸miR-130b-5p會直接附著於CCNG2抑癌基因的3′ 非轉譯區並抑制CCNG2在三陰性乳癌的基因表現,進而增快三陰性乳癌癌細胞的細胞週期。 結論 作者在本篇論文中清楚的的描述信使核糖核酸和微型核糖核酸在三陰性乳癌內的的表現特徵,並提出了一個藉由四十五個預後基因的基因表現來預測三陰性乳癌病患其腫瘤遠處轉移的預測模組。此預測模組在另一個獨立的三陰性乳癌病患族群中也同樣的能夠準確的預估其病患腫瘤復發的可能性。這個由四十五個基因所組成的的預測模型可幫助臨床醫師對三陰性乳癌病患腫瘤遠處轉移的可能性進行初步評估,並以此作為臨床藥物治療的一個輔助參考。此外研究團隊使用高通量定序技術找出在三陰性乳癌和其周遭正常乳房組織有顯著差異表現的微型核糖核酸,並深入探討其在人類癌症腫瘤內的調控機制,此研究成果讓我們對於三陰性乳癌內的微型核糖核酸表現特徵與其對於癌細胞的影響有更清楚的認識。 | zh_TW |
dc.description.abstract | Abstract
Introduction Triple-negative breast cancer, immunohistochemically defined by lacks of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, is a type of breast cancer with aggressive tumor behavior and distinct disease etiology. Due to the lack of an effective targeted medicine, treatment options for triple-negative breast cancer are few and its recurrence rates are high. Recent studies have shown that deregulated gene expression is heavily involved in the progression of human cancer. However, the gene expression characteristics in triple-negative breast cancer are still poorly understood. Moreover, although various multi-gene prognostic markers have been proposed for the prediction of breast cancer outcome in published literatures, most of them were proven clinically useful only for estrogen receptor-positive breast cancers. Reliable identification of triple-negative patients with a favorable prognosis using gene expression data is not yet possible. Methods In this study, clinicopathological information and gene expression microarray data from 51 triple-negative and 106 luminal breast cancers were collected at National Taiwan University Hospital. Gene expression data of triple-negative breast cancer tissues were collected using Agilent oligonucleotide microarrays. Gene expression data along with distant metastasis follow-up information of the triple-negative breast cancer patients were analyzed in this work. In addition, microRNA (miRNA) expression data of 24 triple-negative breast cancers and 14 adjacent normal tissues were analyzed using deep sequencing technology. Expression levels of miRNA reads from each sample were normalized with the quantile-quantile scaling method. Quantitative reverse transcription PCR was performed for validation of deregulated miRNAs in triple-negative breast cancer. Potential target candidates of miRNAs were predicted using the miRanda target prediction algorithm and were further verified using luciferase reporter assays. Previously validated miRNA target genes of the deregulated miRNAs were investigated and their molecular pathways associated with cancer progression were discussed. Results and discussion Hierarchical clustering analysis of the gene expression data revealed that the majority (94%) of triple-negative breast cancers were tightly clustered together carrying strong basal-like characteristics. A 45-gene prognostic signature giving 98% predictive accuracy in distant recurrence of our triple-negative patients was determined using the receiver operating characteristic analysis and leave-one-out cross validation. External validation of the prognostic signature in an independent microarray dataset of 59 early-stage triple-negative patients also obtained statistical significance (hazard ratio 2.29, 95% confidence interval (CI) 1.04-5.06, Cox p = 0.04), outperforming five other published breast cancer prognostic signatures. The 45-gene signature identified in this study revealed that TGF-β signaling of immune/inflammatory regulation may play an important role in distant metastatic invasion of triple-negative breast cancer. Deep sequencing analyses of miRNA expression revealed that a novel 25-miRNA signature was able to effectively distinguish triple-negative breast cancers from surrounding normal tissues. We documented the evidence of seven polycistronic miRNA clusters preferentially harboring deregulated miRNA genes in triple-negative breast cancer. Two of these miRNA clusters (miR-143-145 at 5q32 and miR-497-195 at 17p13.1) were markedly down-regulated in triple-negative breast cancer, while the other five miRNA clusters (miR-17-92 at 13q31.3, miR-183-182 at 7q32.2, miR-200-429 at 1p36.33, miR-301b-130b at 22q11.21, and miR-532-502 at Xp11.23) were up-regulated in triple-negative breast cancer. Noticeably, miR-130b-5p from the miR-301b-130b cluster was shown to directly target the cyclin G2 (CCNG2) tumor-suppressor gene in luciferase reporter assays. Overexpression of miR-130b-5p was shown to significantly repress CCNG2 expression and enhance cell cycle progression in triple-negative breast cancer cells. Conclusions Our work delivers a clear picture of the global messenger RNA and miRNA regulatory characteristics in triple-negative breast cancer. A novel 45-gene prognostic signature was found to be statistically predictive in distant metastasis of triple-negative breast cancer. The 45-gene signature, if further validated, may be a clinically useful tool in risk assessment of distant metastasis for early-stage triple-negative patients. Moreover, miRNA expression of triple-negative breast cancer was measured using deep sequencing technology. A panel of 25 differentially expressed miRNAs identified from 24 triple-negative breast cancers and 14 adjacent normal tissues was found to effectively distinguish triple-negative breast cancers from surrounding normal tissues. Real-time PCR validations of the deregulated miRNAs further supported our findings from the sequencing analyses. The miR-130b-5p-CCNG2 axis identified in this study may play a role in the malignant progression of triple-negative breast cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:34:38Z (GMT). No. of bitstreams: 1 ntu-104-D97945018-1.pdf: 7078886 bytes, checksum: b1bfcc8b351c436a7aa43c8487fdbb1e (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Contents
中文摘要 vii Abstract x Chapter 1 Background 1 1.1 Clinicopathological characteristics of triple-negative breast cancer 3 1.2 Molecular characteristics of triple-negative breast cancer 6 1.3 Clinical outcome of triple-negative breast cancer patients 14 1.4 Specific aims of this study 16 Chapter 2 Gene expression analysis of triple-negative breast cancer 20 2.1 Breast cancer samples and gene expression microarray experiments 20 2.2 Gene expression profiling of triple-negative breast cancer 25 2.3 A 45-gene metastasis predictor signature 30 2.4 External validation of metastasis predictor genes 34 2.5 Functional network topography 37 2.6 Summary 39 Chapter 3 MicroRNA expression analysis of triple-negative breast cancer 40 3.1 Breast cancer and adjacent normal tissues 40 3.2 Deep sequencing microRNA reads 43 3.3 MicroRNA expression profiling of triple-negative breast cancer 45 3.4 Abberant expression of polycistronic microRNA clusters 50 3.5 miR-130b-5p directly targets the cyclin G2 gene 57 3.6 Summary 66 Chapter 4 Discussion 67 4.1 Clinicopathological characteristics 67 4.2 Prognostic evaluation of the 45-gene signature 67 4.3 TGF-β signaling pathway and distance metastasis 69 4.4 The miR-130b-5p-CCNG2 regulatory axis 70 4.5 Validated microRNA targets from literatures 74 Chapter 5 Conclusions 78 Chapter 6 Future work 81 References 86 Supplemental data 106 | |
dc.language.iso | en | |
dc.title | 三陰性乳癌分子生物特徵研究與探討 | zh_TW |
dc.title | Molecular Characterization of Triple-negative Breast Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蔡孟勳,賴亮全,張金堅,謝豐舟,侯明鋒 | |
dc.subject.keyword | 三陰性乳癌,基因表現特徵,微晶片分析,高通量定序分析,微型核糖核酸基因表現, | zh_TW |
dc.subject.keyword | Triple-negative breast cancer,gene expression profiling,microarray analysis,deep sequencing analysis,miRNA expression, | en |
dc.relation.page | 118 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-07-28 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 6.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。